Literature DB >> 33893617

Echocardiographic findings in acromegaly: prevalence of concentric left ventricular remodeling in a large single-center cohort.

J M Hinojosa-Amaya1,2,3, E V Varlamov1,4,2, C G Yedinak1,2, J S Cetas1,2,5, S McCartney1,2, S Banskota1,2, M Fleseriu6,7,8.   

Abstract

PURPOSE: Acromegaly is a rare disease and is associated with increased cardiovascular (CV) morbidity and mortality, especially in patients with uncontrolled disease. We aimed to analyze the prevalence and severity of cardiomyopathy and valvular heart disease in a large cohort of patients with a confirmed acromegaly diagnosis, at baseline and after treatment.
METHODS: We retrospectively reviewed an institutional approved database; 190 patients with confirmed acromegaly and follow-up data available (years 2006-2018). Patients with at least one baseline echocardiogram, were included. Demographic, disease control and echocardiogram variables were collected for analysis.
RESULTS: Of the 190 patients 110 (58%) had a baseline echocardiogram and 43 (39.1%) had at least one follow-up echocardiogram after surgical, medical or multimodal treatment. Baseline left ventricular hypertrophy (LVH) prevalence was 17.8% (64.7% concentric; 35.3% eccentric), diastolic and systolic dysfunction, and overt cardiomyopathy with heart failure were 15.8, 7.9, and 3.0%, respectively. Concentric remodeling of the left ventricle (LV) was noted in 31.4% of patients without LVH. Valve defects were found in 87.3% of patients (14.6% with significant valvular heart disease).
CONCLUSION: Early diagnosis of acromegaly and disease control should be attempted to prevent LVH/LV dysfunction and development of valvular heart disease. Concentric LV remodeling develops prior to obvious LV hypertrophy in almost a third of patients with acromegaly, which is a novel finding. Similar to other epidemiological studies, we found a high prevalence of LVH/LV dysfunction. Although possible, reversal of systolic and diastolic dysfunction is sporadic after treatment of acromegaly.
© 2021. Italian Society of Endocrinology (SIE).

Entities:  

Keywords:  Acromegaly; Echocardiogram; Growth hormone excess; Heart failure; Left ventricular dysfunction; Left ventricular hypertrophy; Valvular disease

Mesh:

Year:  2021        PMID: 33893617     DOI: 10.1007/s40618-021-01579-4

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  27 in total

1.  Overexpression of insulin-like growth factor-1 in mice protects from myocyte death after infarction, attenuating ventricular dilation, wall stress, and cardiac hypertrophy.

Authors:  Q Li; B Li; X Wang; A Leri; K P Jana; Y Liu; J Kajstura; R Baserga; P Anversa
Journal:  J Clin Invest       Date:  1997-10-15       Impact factor: 14.808

2.  Cardiovascular effects of short-term growth hormone hypersecretion.

Authors:  S Fazio; A Cittadini; B Biondi; E A Palmieri; G Riccio; F Bonè; U Oliviero; L Saccà
Journal:  J Clin Endocrinol Metab       Date:  2000-01       Impact factor: 5.958

Review 3.  Acromegaly and the cardiovascular system.

Authors:  Gaetano Lombardi; Mariano Galdiero; Renata S Auriemma; Rosario Pivonello; Annamaria Colao
Journal:  Neuroendocrinology       Date:  2006       Impact factor: 4.914

4.  Pathology of the heart in acromegaly: anatomic findings in 27 autopsied patients.

Authors:  J T Lie
Journal:  Am Heart J       Date:  1980-07       Impact factor: 4.749

Review 5.  Acromegaly and Heart Failure.

Authors:  Annamaria Colao; Ludovica F S Grasso; Carolina Di Somma; Rosario Pivonello
Journal:  Heart Fail Clin       Date:  2019-07       Impact factor: 3.179

6.  Cardioprotective effect of insulin-like growth factor I in myocardial ischemia followed by reperfusion.

Authors:  M Buerke; T Murohara; C Skurk; C Nuss; K Tomaselli; A M Lefer
Journal:  Proc Natl Acad Sci U S A       Date:  1995-08-15       Impact factor: 11.205

7.  Treatment with growth hormone enhances contractile reserve and intracellular calcium transients in myocytes from rats with postinfarction heart failure.

Authors:  M Tajima; E O Weinberg; J Bartunek; H Jin; R Yang; N F Paoni; B H Lorell
Journal:  Circulation       Date:  1999 Jan 5-12       Impact factor: 29.690

8.  Evidence for biventricular involvement in acromegaly: a Doppler echocardiographic study.

Authors:  S Fazio; A Cittadini; D Sabatini; B Merola; A M Colao; B Biondi; G Lombardi; L Saccá
Journal:  Eur Heart J       Date:  1993-01       Impact factor: 29.983

Review 9.  Growth hormone and the heart.

Authors:  L Saccà; A Cittadini; S Fazio
Journal:  Endocr Rev       Date:  1994-10       Impact factor: 19.871

Review 10.  GH and the cardiovascular system: an update on a topic at heart.

Authors:  Jörgen Isgaard; Michele Arcopinto; Kristjan Karason; Antonio Cittadini
Journal:  Endocrine       Date:  2014-06-28       Impact factor: 3.633

View more
  1 in total

Review 1.  Association between insulin-like growth factor-1 and cardiovascular events: a systematic review and dose-response meta-analysis of cohort studies.

Authors:  T Li; Y Zhao; X Yang; Y Feng; Y Li; Y Wu; M Zhang; X Li; H Hu; J Zhang; L Yuan; Y Liu; X Sun; P Qin; C Chen; D Hu
Journal:  J Endocrinol Invest       Date:  2022-05-21       Impact factor: 4.256

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.